Abstract

The human genome project has identified categorized and sequenced most of the 30,000 or so human genes. Recently the ability to perform massively parallel sequencing of the whole genome has increased with the development of next generation and single molecule sequencers. It is speculated that withing the next 2-5yrs it will be possible to sequence whole human genomes for under $1000. Through collaborative networks my lab has archived >600 clinically annotated neuroblastoma, and >100 rhabdomyosarcoma tumor samples. By bioinformatic techniques we are identifying all know targets in neuroblastoma and rhabdomyosarcoma. We are using microarray and next generation sequencing of the pediatric cancer genome. Our goal is to identify activating mutations that can be targeted for therapy in patients with high risk neuroblastoma, rhabdomyosarcoma, and other pediatric cancers for which there is no currently available therapy.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010998-06
Application #
8763297
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2013
Total Cost
$1,326,223
Indirect Cost

  Institution

Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Chang, Wendy; Brohl, Andrew S; Patidar, Rajesh et al. (2016) MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. Clin Cancer Res 22:3810-20
Chen, Justin; Hackett, Christopher S; Zhang, Shile et al. (2015) The genetics of splicing in neuroblastoma. Cancer Discov 5:380-95
Russell, Mike R; Penikis, Annalise; Oldridge, Derek A et al. (2015) CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Res 75:3155-66
Chen, Li; Shern, Jack F; Wei, Jun S et al. (2015) Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet 11:e1005075
Gooskens, Saskia L; Gadd, Samantha; Guidry Auvil, Jaime M et al. (2015) TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney. Oncotarget 6:15828-41
Brohl, Andrew S; Solomon, David A; Chang, Wendy et al. (2014) The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet 10:e1004475
Shah, Nilay; Wang, Jianjun; Selich-Anderson, Julia et al. (2014) PBX1 is a favorable prognostic biomarker as it modulates 13-cis retinoic acid-mediated differentiation in neuroblastoma. Clin Cancer Res 20:4400-12
Li, Samuel Q; Cheuk, Adam T; Shern, Jack F et al. (2013) Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One 8:e76551
Pugh, Trevor J; Morozova, Olena; Attiyeh, Edward F et al. (2013) The genetic landscape of high-risk neuroblastoma. Nat Genet 45:279-84
Abdul-Karim, Ruqayyah; Berkman, Benjamin E; Wendler, David et al. (2013) Disclosure of incidental findings from next-generation sequencing in pediatric genomic research. Pediatrics 131:564-71

Showing the most recent 10 out of 15 publications